Pharmacology, Toxicology and Pharmaceutical Science
Prodrug
100%
HIV
72%
Dolutegravir
60%
Pharmacokinetics
57%
Mouse
40%
Cabotegravir
37%
Nanoparticle
36%
Biodistribution
30%
Infection
30%
Rilpivirine
22%
Viral Clearance
20%
Atazanavir
18%
Lamivudine
18%
Poloxamer
17%
Rhesus Monkey
17%
Abacavir
17%
Matrix Metalloproteinase
14%
Nanocarrier
14%
Hepatitis B Virus
14%
Elimination
14%
Antivirus Agent
13%
Drug Concentration
13%
Folic Acid
13%
Integrase
12%
Drug Formulation
12%
Adverse Event
11%
Drug Release
11%
Human Immunodeficiency Virus 1 Infection
11%
Sustained Release
9%
Chronic Disease
9%
Intramuscular Injection
9%
Integrase Inhibitor
8%
Formulation Design
8%
Europium
8%
Emtricitabine
8%
Human Immunodeficiency Virus 1
8%
Neurologic Disease
7%
Mannose
7%
Heptapeptide
7%
Mouse Model
7%
Amphotericin B
7%
Darunavir
7%
Neutralizing Antibody
7%
Ritonavir
7%
Efavirenz
7%
Drug Delivery System
7%
Magnetite Nanoparticle
7%
Ryanodine Receptor 2
7%
Drug Carrier
7%
Chemokine Receptor
7%
Keyphrases
Prodrug
37%
Cabotegravir
22%
ProTide
22%
Human Immunodeficiency Virus Type 1 (HIV-1)
22%
Nanocrystals
21%
Antiretroviral Therapy
20%
Pharmacokinetic Profile
17%
Long-acting Antiretrovirals
15%
Ultra-long
14%
Dolutegravir
14%
Lipophilic
14%
Humanized Mice
12%
Antiretroviral
10%
HIV-1 Infection
9%
Long-acting Parenteral
9%
Virus
8%
Latent Viral Reservoir
7%
Drug Nanocrystals
7%
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
7%
Long-acting Drug Delivery Systems
7%
Darunavir
7%
Triphosphate
7%
Neurotheranostics
7%
Viral Disease
7%
HBV Replication
7%
Prodrug Therapy
7%
Fragment Condensation
7%
Rhesus Macaque
7%
D-Ser
7%
Multimodal Theranostics
7%
Lamivudine
7%
Pharmacokinetic Evaluation
7%
Core-shell Silica
7%
CRISPR Editing
7%
Europium
7%
Cobalt Ferrite
7%
Folate Receptor
7%
Tenofovir
7%
Drug Entry
7%
Rilpivirine
7%
Cardiovascular Disease
7%
People Living with HIV (PLHIV)
7%
Methylglyoxal
7%
Risk Factors
7%
Early Onset
7%
Depot
6%
Pharmacokinetics
6%
Thiolated chitosan
6%
Monocyte-derived Macrophages
6%
Pronucleotides
6%